Missoulian: Senate immigration bill boosted by border deal
Get the sources behind the stories with recently published government information. Sponsored by the Mansfield Library at the University of Montana.
Friday, June 21, 2013
Wednesday, June 19, 2013
Stalking/ Farm Bill/ Immigration
Missoulian: Justices: Missoula police officer doesn't need to give information to stalker
“Stacy Lear claims she was stalked by Carrie Jamrogowicz
beginning in 2002. In February 2012, Lear sought and obtained a temporary order
of protection against Jamrogowicz in a civil action. Subsequently, Lear
obtained a “no contact” order against Jamrogowicz in a criminal action.
Jamrogowicz moved to have the civil action dismissed with prejudice and Lear
moved to have the civil action dismissed without prejudice. The District Court
granted Lear’s motion and dismissed the civil action without prejudice. Jamrogowicz
appeals. We affirm.”
Missoulian: Montanans wait as U.S. House prepares farm bill
“CBO estimates that, by 2023, enacting S. 744 would lead to
a net increase of 10.4 million in the number of people residing in the United
States, compared with the number of people projected under current law. That
net increase comprises an increase of about 10.4 million permanent residents;
an increase of about 1.6 million temporary workers and their dependents; and a
decrease of about 1.6 million unauthorized residents. (CBO estimates that about
8 million unauthorized residents would initially gain legal status under the
bill, but that change in status would not affect the size of the U.S.
population.)”
Tuesday, June 18, 2013
Government Surveillance/ Anti-Abortion Bill/ Women in the Military
Missoulian: House Intel leaders defend surveillance programs
How Disclosed NSA Programs Protect Americans, and Why Disclosure Aids Our Adversaries
How Disclosed NSA Programs Protect Americans, and Why Disclosure Aids Our Adversaries
Missoulian: House takes up far-reaching anti-abortion bill
H.R.1797: Pain-Capable Unborn Child Protection Act
“Prohibits the abortion from being performed if the probable
post-fertilization age of the unborn child is 20 weeks or greater. Makes an
exception where necessary to save the life of a pregnant woman whose life is
endangered by a physical disorder, illness, or injury, excluding psychological
or emotional conditions…. Prescribes penalties for violations. Bars prosecution
of a woman upon whom an abortion is performed in violation of this Act, but
authorizes such a woman or the father or maternal grandparent of the unborn
child to obtain appropriate relief through a civil action.”
Monday, June 17, 2013
Lower BAC/ Equal Pay/ Generic Drugs
Missoulian: Officials: Lower BAC limit will not lessen Montana's DUI problem
Reaching Zero: Actions to Eliminate Alcohol-Impaired Driving
Reaching Zero: Actions to Eliminate Alcohol-Impaired Driving
“As described in chapter 4, laboratory
studies have shown that driving-related performance is degraded at BAC levels
as low as 0.01, and epidemiological studies employing crash data have shown
significantly elevated crash risk at BAC levels near 0.05. Lowering per se BAC
limits has been associated with reductions in impaired driving crashes and
fatalities. For example, 14 independent studies conducted in the United States
found that lowering the BAC limit from 0.10 to 0.08 resulted in reductions in
alcohol-related crashes, fatalities, or injuries of 5–16 percent (Fell and Voas
2006, 233–43). Other studies have found similar results (for example, Dee 2001,
111–28; Shults and others 2001, 66–88; Voas, Tippetts, and Fell 2000, 483–92).
In 2012, the CDC listed 0.08 per se BAC laws among the “top 20 violence and
injury practice innovations since 1992” (Kress and others 2012, 257–63).27”
“Respondent Solvay
Pharmaceuticals obtained a patent for its approved brand-name drug AndroGel. Subsequently,
respondents Actavis and Paddock filed applications for generic drugs modeled
afterAndroGel and certified under paragraph IV that Solvay’s patent was invalid
and that their drugs did not infringe it. Solvay sued Actavis and Paddock,
claiming patent infringement. See 35 U. S. C. §271(e)(2)(A). The FDA eventually
approved Actavis’ generic product, but instead of bringing its drug to market,
Actavis entered into a “reverse payment” settlement agreement with Solvay,
agreeing not to bring its generic to market for a specified number of years and
agreeing to promote AndroGel to doctors in exchange for millions of dollars.
Paddock made a similar agreement with Solvay, as did respondent Par, another
manufacturer aligned in the patent litigationwith Paddock.”
Subscribe to:
Posts (Atom)